Kura Oncology (KURA) announced that Mollie Leoni has been promoted to chief medical officer after serving as executive VP of clinical development and clinical lead for the company’s ziftomenib program since 2020. In addition, Francis Burrows has been promoted to chief scientific officer after leading the company’s translational research efforts for the past nine years. Stephen Dale has stepped down as chief medical officer, effective as of January 2, to focus on recovery from personal health challenges.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology, Kyowa Kirin report data on KOMET-007 at ASH meeting
- Kura Oncology holds a pharmaceutical update conference call
- Kura Oncology management to meet with Cantor Fitzgerald
- BofA lowers Kura Oncology price target to $29, sees buying opportunity
- Nvidia reports Q3 beat, Starbucks explores China partnerships: Morning Buzz